Star Health & Allied Insurance Upgraded to Hold on Financial and Technical Improvements

Financial Performance: From Negative to Flat Trend

The primary catalyst behind the upgrade lies in the company’s financial trend, which has improved from negative to flat over the last quarter. Star Health reported its highest-ever quarterly net sales at ₹4,566.27 crore for December 2025, marking a significant milestone in top-line growth. However, the profit after tax (PAT) for the latest six months stood at ₹183.12 crore, reflecting a decline of 43.9% compared to the previous period. This contraction in profitability remains a concern, but the moderation in the rate of decline has been viewed positively by analysts.

The financial trend score improved from -10 to -4 over the past three months, indicating that while earnings pressures persist, the company is no longer on a steep downward trajectory. This stabilisation is critical in the insurance sector, where sustained profitability is essential for long-term viability. Star Health’s operating profit growth remains robust at a compound annual growth rate (CAGR) of 19.27%, underscoring the company’s underlying operational strength despite short-term earnings volatility.

Valuation: Expensive but Justified by Institutional Confidence

Star Health’s valuation remains on the expensive side, trading at a price-to-book (P/B) ratio of 3.7, which is a premium relative to its peers’ historical averages. The company’s return on equity (ROE) is modest at 6%, which raises questions about the justification for such a valuation premium. However, the high institutional holding of 35.03% suggests that sophisticated investors continue to back the stock, likely due to its strong fundamentals and growth potential.

Despite the premium valuation, the stock has delivered an 8.25% return over the past year, outperforming the Sensex’s 5.16% gain during the same period. This relative outperformance, coupled with the company’s strong operating profit growth, supports the Hold rating, signalling that while the stock is not a bargain, it remains a viable investment for those seeking exposure to the insurance sector.

Technical Analysis: Shift to Mildly Bullish Indicators

The technical outlook for Star Health has also improved, contributing to the upgrade. The technical trend has shifted from mildly bearish to mildly bullish, supported by several key indicators. On a daily basis, moving averages have turned bullish, signalling positive momentum in the short term. Meanwhile, weekly and monthly MACD readings remain mildly bearish, but the weekly Dow Theory indicator has turned mildly bullish, suggesting a potential trend reversal.

Other technical signals such as the Relative Strength Index (RSI) and Bollinger Bands indicate a sideways movement, reflecting consolidation rather than a clear directional bias. The KST oscillator remains bearish on both weekly and monthly charts, indicating some caution among traders. Overall, the mixed but improving technical signals justify a more optimistic stance compared to the previous rating.

Quality Assessment: Strong Fundamentals Amidst Profitability Challenges

Star Health’s quality grade remains solid, supported by its strong long-term fundamentals. The company has demonstrated a 19.27% CAGR growth in operating profits, a key metric that highlights operational efficiency and business resilience. Institutional investors’ confidence, with holdings exceeding 35%, further underscores the company’s quality credentials.

However, the company’s net sales growth has been disappointing over the long term, with an annualised decline of 50%. This stark contrast between operating profit growth and sales contraction points to challenges in scaling revenue while maintaining profitability. The flat financial performance in the recent quarter and the significant drop in PAT highlight ongoing headwinds that investors must consider.

Comparative Returns and Market Context

Star Health’s stock has outperformed the Sensex over multiple short-term periods, delivering a 10.78% return in the past week and 5.05% over the last month, while the benchmark index declined by 1.00% and 4.67% respectively. Year-to-date, the stock has gained 3.58% compared to the Sensex’s 5.28% loss. Over the one-year horizon, the stock’s 8.25% return also surpasses the Sensex’s 5.16% gain.

However, the longer-term three-year return of -3.76% contrasts sharply with the Sensex’s 35.67% gain, reflecting the company’s struggles to sustain growth over extended periods. This divergence emphasises the importance of cautious optimism and the rationale behind the Hold rating rather than a more aggressive Buy recommendation.

Conclusion: A Balanced Hold Recommendation

The upgrade of Star Health & Allied Insurance Company Ltd’s rating from Sell to Hold reflects a nuanced assessment of its current position. The company’s financial trend has stabilised, and technical indicators have improved, signalling a potential turnaround in momentum. Strong operating profit growth and institutional backing provide a solid foundation, even as profitability challenges and valuation concerns temper enthusiasm.

Investors should weigh the company’s premium valuation and recent earnings decline against its operational strengths and market outperformance in the short term. The Hold rating suggests that while Star Health is not currently a compelling buy, it remains a stock worth monitoring for signs of sustained recovery and growth.

With a current market price of ₹471.30, close to its 52-week high of ₹533.90 and well above its 52-week low of ₹330.05, the stock’s price action reflects cautious investor optimism. The company’s ability to convert its strong fundamentals into consistent profitability will be key to any future upgrades in rating.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →